bioAffinity Technologies announced a 100% increase in sales for its CyPath Lung test through Q3 2026 compared to Q3 2025, indicating strong clinical adoption. This significant growth suggests increasing market penetration and potential for future revenue expansion for the company.
bioAffinity Technologies (BIAF) reported a substantial 100% increase in sales for its CyPath Lung test through Q3 2026, alongside an 89% increase in ordering physicians and a 48% year-over-year sales volume increase from existing physicians. This indicates strong market acceptance and growing demand for their noninvasive lung cancer detection test. For traders, this is a positive short-term catalyst, suggesting the company is successfully commercializing its product and expanding its customer base. The long-term implication is potential for sustained revenue growth and improved financial performance, making BIAF an attractive opportunity for investors looking for growth in the biotechnology sector, particularly in diagnostics.